Lasa & ICT explore Favipiravir therapy to fight COVID 19

Mumbai, March 16, 2020: API major, Lasa Supergenerics Ltd in collaboration with Institute of Chemical Technology (ICT) recently announced commencement for Development of antiviral Compound Favipiravir as Covid19 Treatment.

Commenting on the development, Dr Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said Health and safety of our countrymen is of pristine importance and to safeguard them from deadly corona we have joined hands with one of Government recognised Institute in India “Institute of Chemical Technology” to develop Favipiravir for Treatment of “COVID19” which has currently emerged as pandemic.

We are working together with all our efforts to commence the research and scale up activity of Favipiravir, antiviral drug, showing its promising activity for inhabitation of wide range of viruses, we will take necessary steps for getting permission from Drug Controller General of India to Launch product in Indian Market at the earliest, Once the Favipiravir therapy is approved by global regulatory authorities we would approach DCGI for conducting required bioequivalence clinical trials in India and also seek for strategic private investments and/or Government aid to commercialise this product subject to all regulatory approvals and trials.

About ICT, Institute of Chemical Technology (ICT) Formerly the University Department of Chemical Technology (UDCT) is a Public deemed University specialized in Chemical Technology located in Mumbai, India. It is focused in training and research in various branches of chemical engineering, chemical technology and pharmacy.

Commenting on the Collaboration, Dr Vikas Terlvekar, Professor– Institute of Chemical Technology (ICT) Said, we appreciate this great step by Lasa Supergenerics Ltd and Dr.Omkar which shall help nation and support government to treat this deadly Covid-19, we have accepted the challenge to fight against virus with each other’s support and expect to succeed the battle.

About Favipiravir, Favipiravir is an antiviral drug and is a promising antidote for the treatment of Coronavirus disease (COVID-2019). It possesses activity against many RNA viruses. It is a guanine analogue approved for influenza treatment. It can effectively inhibit the RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikungunya, norovirus and enterovirus, and a recent study reported its activity against 2019-nCoV.

About Lasa (BSE: 540702; NSE: LASA) Incorporated in 2011, Lasa is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea etc.

For more information contact: Mr. Hitesh Wadhwani Ms. Amruta Desai
Lasa Supergenerics Ltd. Concept PR
Tel: 7798888147 Tel: +022 40558980
E-mail: hitesh@lasalabs.com M: +91 9867891235
E-mail:amruta@conceptpr.com